On Wednesday, Following Stocks were among the “Top Gainers” In U.S. Stock Exchange: Direxion Shares Exchange Traded Fund Trust (NYSEARCA:EDC), Can-Fite BioPharma Ltd. (NYSEMKT:CANF), New Gold Inc. (USA) (NYSEMKT:NGD), Goodrich Petroleum Corporation (NYSE:GDP)
Direxion Shares Exchange Traded Fund Trust (NYSEARCA:EDC)’s shares picked up 7.47%, and closed at $23.89. The stock has the beta value of 3.68, and its volatility for the week is 4.19%, while for the month it is 2.82%. The company has the market capitalization of $237.37M.
The investment seeks daily investment results, before fees and expenses, of 300% of the performance of the MSCI Emerging Markets IndexSM. The fund creates long positions by investing at least 80% of its assets in the securities that comprise the MSCI Emerging Markets IndexSM and/or financial instruments that provide leveraged and unleveraged exposure to the index. These financial instruments comprise: futures contracts; options on securities, indices and futures contracts; equity caps, floors and collars; swap contracts; forward contracts; short positions; reverse repurchase contracts; exchange-traded funds; etc. It is non-diversified.
Can-Fite BioPharma Ltd. (NYSEMKT:CANF), raised 7.37%, and closed at $4.66. The company holds the market capitalization of 41.57M. Its 20-day moving average gained 7.26%, below 50-day moving average of 19.84%, below 200-day moving average of 27.20% from the latest market price of $4.66. The mean recommendation of analysts for this stock is 2.00.(where 1=Buy, 5=Sale).
Can-Fite BioPharma, Ltd., a clinical-stage biotechnology corporation, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and ophthalmic diseases. The corporation principally develops CF101 that is in Phase III study for the treatment of psoriasis, in addition to accomplished Phase II study for the treatment of rheumatoid arthritis; accomplished Phase III study for the treatment of dry eye; accomplished Phase II study for the treatment of glaucoma; and initiating a Phase II study of CF101 for the treatment of uveitis.
New Gold Inc. (USA) (NYSEMKT:NGD), enhanced 7.27%, and closed at $3.69. The company has the market capitalization of $1.74B. The beta value of the stock is 0.09. On the other hand the stock’s volatility for the week is 6.95%, and for the month is 5.90%. The stock’s price to book ratio is $0.69, however price to sale ratio is $2.61. Analyst’s mean recommendation regarding this stock is 2.70. (where 1=Buy, 5=Sale).
New Gold Inc. is engaged in gold mining and related activities, counting attainment, exploration, extraction, processing and reclamation. Its operating assets comprise of the Mesquite gold mine (Mesquite Mine) in the United States, the Cerro San Pedro gold-silver mine (Cerro San Pedro Mine) in Mexico, and the Peak gold-copper mines in Australia.
Goodrich Petroleum Corporation (NYSE:GDP), rose 7.26%, and closed at $3.25. The stock volatility for the week is 11.17%, while for the month remained 9.82%. The company holds consensus target price of $4.41.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed -8.60 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained -188.30% and Annual EPS growth for the past 5 years is considered as -3.80%.
The mean recommendation of analysts for this stock is 3.00. (where 1=Buy, 5=Sale).
Goodrich Petroleum Corporation is an independent oil and natural gas corporation. The Corporation is engaged in the exploration, development and production of oil and natural gas. The Corporation’s properties are primarily in South Texas, which comprises the Eagle Ford Shale Trend, Northwest Louisiana and East Texas, which comprises the Haynesville Shale and Cotton Valley Taylor Sand and Southwest Mississippi and Southeast Louisiana which comprises the Tuscaloosa Marine Shale.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
